Key Highlights

  • High Staff Productivity: Apotex's profit-per-employee figure of approximately CAD 60.13 thousand reflects sizable fiscal 2026 Net Income across a team of more than 6,000 people.
  • Scaled Generics Model: Conventional generics, specialty generics, brands and Biosimilars across Canada, the United States and international markets share manufacturing, regulatory and distribution capacity.
  • Balanced Growth Outlook: Debt reduction after the IPO and new semaglutide launches support the outlook, while US pricing and loss of one-off product Revenue require careful reading.

Company Overview and Business Model

Apotex Health Corp. (TSX:APTX) describes itself as Canada's largest pharmaceutical company. It develops, manufactures and sells conventional generics, specialty generics, brands and biosimilars, serving Canada, the United States and international markets, and reports in Canadian dollars.

The company completed an upsized initial public offering in June 2026 at CAD 24 per share, with CAD 850.0 million of gross proceeds going to the company, and the remainder sold by existing holders.

The shares trade at a current share price of CAD 33.70. Fiscal 2026, the year ended March 31, 2026, brought revenue of about CAD 3,491 million, and the company has more than 6,000 employees worldwide.

Net Income Performance and Earnings Strength

Fiscal 2026 net income was approximately CAD 373.8 million, the sum of its quarterly results, versus CAD 151.7 million the year before.

The first quarter of fiscal 2027, ended June 30, 2026, produced a net loss of CAD 38.3 million, or CAD 0.19 per share, as share-based compensation reached CAD 102.7 million, including CAD 72.8 million from plan modifications tied to the listing.

An unrealized foreign-exchange loss of CAD 23.8 million, against a gain of CAD 35.5 million a year earlier, and IPO-related costs of CAD 20.8 million added to the loss.

Adjusted net income was CAD 142.2 million, versus CAD 174.6 million for the prior-year quarter excluding generic Revlimid, showing that the loss came mainly from non-recurring and non-cash items.

Revenue Growth and Profit Margin Analysis

First-quarter revenue was CAD 848.0 million, down 25.8% from CAD 1,142.3 million because the prior-year quarter included CAD 307.8 million of generic Revlimid revenue. Excluding that, revenue rose 1.6% from CAD 834.5 million.

By region, Canada grew 11.5% to CAD 412.7 million, the United States fell 8.6% excluding the earlier Revlimid sales to CAD 362.9 million, and international revenue rose 7.9% to CAD 72.4 million.

By business line, conventional generics earned CAD 430.8 million, specialty generics CAD 256.2 million and brands and biosimilars CAD 161.0 million. Gross margin was 49.7%, compared with 52.1% a year earlier excluding Revlimid.

Adjusted EBITDA was CAD 259.3 million, a 30.6% margin, in line with CAD 259.5 million and 31.1% in the prior-year quarter excluding Revlimid.

High Profit Per Employee: A Key Productivity Indicator

Apotex's profit-per-employee figure of approximately CAD 60.13 thousand shows the net income generated relative to the size of its team, an indicator that reflects both the scale of its Manufacturing network and the effect of unusual items in fiscal 2026.

The standard calculation is:

Profit Per Employee = Net Income ÷ Average Number of Employees

Fiscal 2026 net income of about CAD 373.8 million and a headcount of more than 6,000 imply roughly CAD 62 thousand per person, broadly consistent with the CAD 60.13 thousand indicator.

The comparison needs care. Fiscal 2026 benefited from generic Revlimid revenue that is not expected to recur, and the first quarter of fiscal 2027 produced a loss, so the ratio on a trailing basis would be far lower.

The structure supports high per-person profit during favorable periods: a large product portfolio, shared regulatory expertise and established plants allow the company to launch generics with limited incremental staff.

Key Business Drivers Supporting High Profit Per Employee

Canadian Leadership: Canadian revenue grew 11.5% in the first quarter, supported by launches of generic semaglutide products.

Semaglutide Launches: Health Canada approved Apo-Semaglutide in May 2026 and Sevmia, the first generic Wegovy equivalent in Canada, in June 2026.

Product Mix and Acquisitions: The July 2026 purchase of Cumberland's US portfolio for CAD 141.8 million adds assets, and Infuvite launches in the US contribute.

Cost Productivity: Initiatives target more than CAD 100 million of in-year savings.

Risks Investors Need to Consider

US generics face pricing pressure, and US revenue declined 8.6% excluding generic Revlimid, with some product pauses noted.

Fiscal 2026 net income included revenue from a product that is not repeating, which makes year-over-year comparisons difficult.

Net debt remains CAD 2,174.7 million, so interest rates and refinancing conditions matter for earnings.

Launches such as generic semaglutide face competition and Patent timelines, particularly outside Canada where expiry runs to 2032 in the US.

Bull Case: What Could Support Further Earnings Growth?

  • Debt fell and Leverage is now below the company's long-term target.
  • Semaglutide launches in Canada could add a new revenue line.
  • Productivity programs could lift margins toward or above the 30% adjusted EBITDA target.
  • Management expects double-digit growth in the second half of fiscal 2027.

Bear Case: What Could Challenge Net Income Sustainability?

  • US pricing pressure could weigh on generic revenue.
  • Net income may remain volatile due to foreign-exchange and compensation items.
  • Revlimid revenue is not expected to return, limiting comparisons.
  • Launch execution and competition may fall short of the roughly 10% of revenue targeted.

Financial Strength, Cash Flow, and Earnings Quality

At June 30, 2026, cash was CAD 258.8 million and total debt CAD 2,433.4 million, giving net debt of CAD 2,174.7 million, compared with CAD 2,883.2 million at March 31, 2026.

Operating Cash Flow was CAD 29.3 million in the quarter, versus CAD 406.6 million a year earlier, while operating free cash flow was CAD 142.0 million. The first number reflects timing and listing-related payments.

After quarter end, the revolver was increased to CAD 1.2 billion and extended to July 2031, with facilities becoming unsecured and a Credit agency assigning an investment-grade issuer rating.

A quarterly Dividend of CAD 0.06 per share was payable September 30, 2026, to holders of record on September 15, 2026.

Recent Company Developments and Earnings Catalysts

On August 12, 2026, the company reported first-quarter fiscal 2027 results, noting that leverage had fallen below its long-term target.

Fiscal 2027 guidance calls for upper mid-single-digit revenue growth, an adjusted EBITDA margin of about 30%, double-digit growth in the second half and launch revenue near 10% of total.

The company filed a base shelf prospectus on August 11, 2026, and in July 2026 launched four US configurations of generic Infuvite, two with Competitive Generic Therapy exclusivity.

In April 2026 the US regulator granted tentative approval to a generic Ozempic, with launch expected after final approval following patent expiry in 2032.

What Investors Need to Watch Next

Shares fell 0.62% in the latest session.

Apotex has scheduled its second-quarter fiscal 2027 results for November 12, 2026, at about 6:00 a.m. Eastern time, with a webcast at 8:00 a.m.

Elements to follow include Canadian semaglutide uptake, US performance, gross margin and progress toward the full-year margin target.

Cash flow, debt reduction and the effect of share-based costs will show how much of net income converts to cash once listing effects fade.